Polyrizon announced a partnership with a leading global pre‑clinical contract research organization to conduct ISO 10993 biocompatibility studies under Good Laboratory Practice standards. The studies, covering cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity, and pyrogenicity, are slated to begin in the second quarter of 2026.
The agreement is a pivotal regulatory milestone that will generate the data required for FDA submissions and enable the company to move its Capture‑and‑Contain hydrogel nasal spray platform, PL‑14, into human trials later in 2026. By outsourcing these studies, Polyrizon can leverage CRO expertise, maintain data quality, and accelerate its development timeline while mitigating regulatory risk.
CEO Tomer Izraeli said, "This agreement marks an important step in the advancement of our development program." The statement underscores the company’s focus on building a robust safety dossier and advancing toward clinical testing.
Polyrizon’s progress has attracted strong investor interest, with the company’s stock reflecting confidence in its cumulative milestones, including GMP manufacturing of clinical trial material, a successful FDA pre‑submission meeting, and now this CRO agreement.
The biocompatibility studies will be conducted under ISO 10993 and GLP, ensuring that the data meet international safety standards. Successful completion will strengthen the safety dossier, support future FDA submissions, and could shorten the time to market for PL‑14, enhancing the company’s commercial prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.